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Abstract 
Background: Streptomyces, as the main source of antibiotics, has been intensively exploited for discovering new 
drug candidates to combat the evolving pathogens. Disruption of wblA, an actinobacteria-specific gene controlling 
major developmental transition, can cause the alteration of phenotype and morphology in many species of Strepto-
myces. One wblA homologue was found in Streptomyces ansochromogenes 7100 by using the Basic Local Alignment 
Search Tool. It is interesting to identify whether novel secondary metabolites could be produced by the wblA disrup-
tion mutant as evidenced in other Streptomyces.
Results: The wblA disruption mutant of S. ansochromogenes 7100 (ΔwblA) was constructed by homologous recom-
bination. ΔwblA failed to produce spores and nikkomycin, the major product of S. ansochromogenes 7100 (wild-type 
strain) during fermentation. Antibacterial activity against Staphylococcus aureus and Bacillus cereus was observed 
with fermentation broth of ΔwblA but not with that of the wild-type strain. To identify the antibacterial compounds, 
the two compounds (compound 1 and compound 2) produced by ΔwblA were characterized as 16-membered 
macrolides by mass spectrometry and nuclear magnetic resonance spectroscopy. The chemical structure of these 
compounds shows similarity with tylosin, and the bioassays indicated that the two compounds inhibited the growth 
of a number of gram-positive bacteria. It is intriguing that they displayed much higher activity than tylosin against 
Streptococcus pneumoniae.
Conclusions: Two novel tylosin analogues (compound 1 and 2) were generated by ΔwblA. Bioassays showed that 
compound 1 and 2 displayed much higher activity than tylosin against Streptococcus pneumoniae, implying that 
these two compounds might be used to widen the application of tylosin.
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Background
The crisis of antibiotic resistance has become an impend-
ing global problem, so novel antibiotics are required 
to combat the evolving pathogens and new emerging 
diseases. More than half of medically important anti-
microbial and antitumor antibiotics are produced by 
Streptomyces. Genome engineering and gene manipu-
lation on secondary metabolic gene clusters have been 
widely applied for exploring novel bioactive agents. For 
example, using heterologous expression, a 157  kb dap-
tomycin biosynthetic gene cluster from Streptomyces 
roseosporus NRRL 15998 was successfully cloned and 
heterologously expressed in Streptomyces coelicolor [1]. 
Two hybrid antibiotics were generated by genetic manip-
ulation of the nikkomycin and polyoxin biosynthetic 
gene clusters [2]. Supplementation of the mutasynthesis 
strain with nicotinic acid led to the production of two 
novel nikkomycin analogues [3]. However, sequencing of 
several Streptomyces genomes revealed that a large num-
ber of antibiotic biosynthetic gene clusters are present, 
which have the potential to produce many more natu-
ral products than had previously been recognized [4–7]. 
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Therefore, it has become necessary to devise methods 
and strategies to identify valuable natural products. One 
of the features of antibiotic synthesis in Streptomyces is 
that the production of antibiotics is generally associated 
with the development and differentiation of Strepto-
myces. Genetic manipulations of pleiotropic regulators 
responsible for both differentiation and antibiotic pro-
duction may effectively influence the expression of cer-
tain genes involved in metabolic pathways, thus it would 
be an efficient strategy for searching novel metabolites. 
By this approach, comprehensive elucidations on biosyn-
thetic pathways or regulatory mechanisms of the metab-
olite biosynthesis could be circumvented.
whi genes are involved in the life cycle of Streptomy-
ces as well as in the production of various antibiotics [8]. 
Disruption of these genes resulted in white phenotype of 
aerial hyphae in Streptomyces, so they were named as whi 
genes. whiB gene was originally discovered in Streptomy-
ces coelicolor, and whiB-like (wbl) genes are widespread 
in Streptomyces [9, 10]. There are at least 11 homologues 
of whiB genes on the chromosome of S. coelicolor. Muta-
tion or absence of wblA caused multiple effects on Strep-
tomyces, such as the failure of sporulation, enhancement 
of actinorhodin, undecylprodigiosin, doxorubicin, tauto-
mycetin, and moenomycin production [9, 11–13]. There-
fore, WblA is recognized as a global regulator. It plays 
as a repressor of antibiotic production in S. coelicolor, 
but acts as a pivotal activator for natamycin biosynthesis 
in Streptomyces chattanoogensis L10 [14]. Streptomyces 
ansochromogenes 7100, a natural peptidyl nucleoside anti-
biotic nikkomycin producer, has been studied for decades 
[15]. Like other well-studied Streptomyces, it has a typical 
life cycle of differentiation and development with aerial 
mycelia and spore formation accompanied by second-
ary metabolites biosynthesis. In search of the sequenced 
genome of S. ansochromogenes, a whiB-like gene situated 
on the chromosome was found and its encoding protein 
shares 96 % identity with WblA in S. coelicolor, likewise it 
was named as wblA (gene accession number KT583835).
In this study, we focused on the secondary metabolites 
produced by the wblA disruption mutant of S. ansochro-
mogenes 7100 (ΔwblA). It is intriguing that ΔwblA failed 
to produce nikkomycin but led to the discovery of novel 
active metabolites simultaneously. These compounds 
were subsequently isolated, purified and analyzed for 
their structures and bioactivities against a number of 
bacteria.
Results
Construction of wblA disruption mutant and its 
complementation
In order to identify whether the metabolite profile could 
be affected by wblA disruption in S. ansochromogenes 
7100, ΔwblA was constructed via homologous recom-
bination. As expected, ΔwblA failed to form grey spores 
and spore chains on minimal medium (MM) agar in com-
parison with wild-type (WT) strain (Fig.  1a–c). On the 
other hand, nikkomycin, the only secondary metabolite 
identified so far from this strain, was examined. Cultures 
from the same time-course experiments were subjected 
to bioassays against Alternaria longipes and Candida 
albicans for nikkomycin activity test (Fig. 2a, b). In con-
trast to WT strain, no inhibition zone was observed 
against above two indicator strains with the fermentation 
filtrate of ΔwblA. High-performance liquid chromatog-
raphy (HPLC) analysis demonstrated that the produc-
tion of nikkomycin was completely abolished in ΔwblA 
(Fig. 2c). To further verify the effect of wblA disruption 
on nikkomycin production, the transcription profile of 
genes involved in nikkomycin biosynthesis was analyzed 
by quantitative Real Time Polymerase Chain Reaction 
(qRT-PCR). The biosynthetic gene cluster of nikkomy-
cin includes one pathway-specific regulatory gene (sanG) 
and 21 structural genes consisting of three transcriptional 
units (sanO-V, sanN-I and sanF-X) [16]. The first gene 
of each transcriptional unit was chosen to examine the 
transcription of corresponding genes. The results showed 
that transcriptions of sanG and other three genes (sanN, 
sanO and sanF) situated in each transcriptional unit were 
all not detected in ΔwblA, whereas the transcription of 
hrdB as internal control, encoding the principal sigma-
like factor, was not affected by the disruption of wblA 
(Fig. 2d). Complementary experiment was performed by 
integrating a copy of wblA and pSET152 vector into the 
chromosome of ΔwblA, respectively. As expected, nikko-
mycin production in ΔwblA was restored as that in WT 
strain (Fig. 2a–c). These results demonstrated that wblA 
is essential for nikkomycin biosynthesis in S. ansochro-
mogenes 7100. Disruption of this gene affected not only 
the spore formation but also the nikkomycin biosynthe-
sis, implying that wblA possesses multiple functions.
Analyses of the secondary metabolites of ΔwblA
Based on the fact that nikkomycin production was abol-
ished in ΔwblA, it is noteworthy to identify whether new 
products could be produced by ΔwblA. The culture fil-
trates from the different time-course experiments were 
subjected to bioassays against representative gram-pos-
itive bacteria and gram-negative bacteria (Additional 
file 1: Table S1). The culture filtrate collected from ΔwblA 
after incubation for 96  h showed clear inhibition zones 
against both Staphylococcus aureus and Bacillus cereus, 
whereas no inhibition zone was found in the culture fil-
trate from WT (Fig.  3a, b). Chloroform extracts from 
these cultures were further analyzed by HPLC (Fig. 3c), 
and distinct peaks appeared at 17 min (compound 1) and 
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18 min (compound 2) in the extract of ΔwblA (Fig. 4a). 
Both compounds gave rise to distinctive absorption at 
wavelength 286  nm on the ultra-violet (UV) spectra 
(Fig. 4b), indicating that they might be new products gen-
erated by ΔwblA since these two compounds were not 
found in WT under the same conditions.
Isolation and structural analyses of compound 1 and 2
To determine the chemical structures of compound 1 
and 2, 18 liters of fermentation broth of ΔwblA in SP 
medium was harvested and extracted with chloroform. 
The organic phase was concentrated and applied onto 
Sephadex LH-20 column for further purification. 2.3 mg 
of compound 1 and 5.2 mg of compound 2 were obtained 
after final separation by semi-preparative HPLC. The 
chemical structures of these two compounds were deter-
mined by Mass Spectrometry (MS) and Nuclear Mag-
netic Resonance (NMR) spectroscopy.
High resolution positive-ion electron spray ionization 
mass spectrometry (HR-ESI–MS) of compound 1 gave a 
molecular ion peak at m/z 577.33459 ([M+Na−H2O]+) 
and the molecular formula was found to be C29H48O11. 
An initial survey of 1H NMR and 13C NMR spectra 
(Fig. 5a, b) indicated the existence of two conjugated dou-
ble bonds, a mycinose moiety and two carbonyl carbons 
(δC 174.7 and 204  ppm). Cross peaks between δH (4.98, 
1.92 and 2.5 ppm) and δC 174.7 ppm on HMBC indicated 
that compound 1 could contain a macrolide backbone. 
Along with other correlations (Additional file  1: Figure 
S1) between protons and carbons on HMBC, HSQC and 
1H–1H COSY, compound 1 seemed to be an analogue of 
tylosin, and most signals on the lactone and mycinose 
moiety could be assigned based on the NMR data of 
tylosin, except those at positions C5 and C6 [17]. Pro-
ton and carbon resonances for the two sugar moieties at 
C5 and acetaldehyde group at C6 in tylosin were absent, 
but two additional hydroxyl groups were present as indi-
cated by the two sets of signals (δH 4.1, δC 71.6 ppm; δH 
4.3, δC 67.9 ppm), which were determined by the follow-
ing analysis. A cross peak between H4 (δH 1.48 ppm) and 
δH 4.1  ppm on 1H-1H COSY indicated that δH 4.1  ppm 
and δC 71.6 ppm could be assigned to C5; while the cor-
relation between δH 4.3 ppm and δC 71.6 ppm on HMBC 
suggested that δH 4.3  ppm and δC 67.9  ppm could be 
Fig. 1 Effects of wblA disruption on the phenotype and morphological differentiation of S. ansochromogenes 7100. Observations on the phenotype 
of S. ansochromogenes 7100 and its derivatives from both sides of the plate (a, b), and the scanning electron micrographs of the mycelia and spores 
(c). (I): ΔwblA, (II): S. ansochromogenes 7100, (III): complemented strain by integrating a copy of wblA into the chromosome of ΔwblA, (IV): the control 
strain by integrating pSET152 vector into the chromosome of ΔwblA
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assigned to C6. Combined with other NMR data, com-
pound 1 was determined as 6-hydroxy-21-O-mycinosylt-
ylactone (Fig. 5c), a novel tylosin analogue.
For compound 2, HR-ESI–MS gave a molecular ion 
peak at m/z 602.38965 ([M+NH4]+) and the molecu-
lar formula was found to be C31H52O10. Comparison of 
the 1H NMR and 13C NMR data (Fig.  5d, e) with those 
of compound 1 indicated a highly structural similarity 
between the two compounds, and the only difference is 
at C6. δH 4.3  ppm and δC 67.9  ppm at C6 were absent 
and the chemical shift at C6 was high-field shifted to δC 
38  ppm in compound 2. Meanwhile, two sets of extra 
signals (δC 22.7 ppm and δH 1.62 ppm; δC 9.4 ppm and δH 
0.92 ppm) showed the existence of an ethyl group, while 
the correlation between δH 0.92 ppm and C6 (δC 38 ppm) 
confirmed that the ethyl group is attached to C6. Further 
analysis of the HMBC, HSQC and COSY data (Addi-
tional file 1: Figure S2), compound 2 was determined as 
another tylosin analogue and designated as 23-O-myci-
nosyltylactone (Fig. 5f ).
The NMR spectroscopic data of compound 1 and com-
pound 2 are summarized in Table  1. The structural dif-
ferences among compound 1, 2 and tylosin are illustrated 
(Fig. 5g).
Fig. 2 Effects of wblA disruption on nikkomycin production. a The bioassay of nikkomycin against Alternaria longipes. b The bioassay of nikkomy-
cin against Candida albicans. c HPLC analysis of nikkomycin. d Transcription analysis of genes related to nikkomycin biosynthesis by qRT-PCR; the 
transcript of hrdB was used as an internal control. (I): ΔwblA, (II): S. ansochromogenes 7100, (III): complemented strain by integrating a copy of wblA 
into the chromosome of ΔwblA, (IV): the control strain by integrating pSET152 vector into the chromosome of ΔwblA. Arrows indicate the peak of 
nikkomycin on HPLC produced by S. ansochromogenes 7100
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Bioassays of compound 1 and 2
Structural elucidation showed compound 1 and com-
pound 2 are 16-membered glycosylated macrolides. 
The functional groups responsible for the antibacte-
rial activity of 16-membered macrolides are generally 
thought to be the aldehyde and the 9-keto group on 
Fig. 3 Bioassays and HPLC analysis of the fermentation broth from S. ansochromogenes 7100 and ΔwblA. Bioassays of the fermentation broth 
against Staphylococcus aureus (a) and Bacillus cereus (b), and the HPLC analysis (c). (I): ΔwblA, (II): S. ansochromogenes 7100, (III): complemented strain 
by integrating a copy of wblA into the chromosome of ΔwblA, (IV): the control strain by integrating pSET152 vector into the chromosome of ΔwblA. 
Arrows indicate the new appeared peaks on HPLC produced by ΔwblA
Page 6 of 11Lu et al. Microb Cell Fact  (2015) 14:173 
the lactone, dimethylamino or methoxyl group on the 
sugar moieties and ethyl group at position C15 (Fig. 5g) 
[18]. In preliminary assays performed by disk diffusion 
tests, the fermentation filtrate of ΔwblA showed inhibi-
tory activity against gram-positive pathogenic bacteria 
(Additional file 1: Table S1). MIC (minimum inhibitory 
concentration) values were then determined with puri-
fied compound 1 and compound 2 against a variety 
of gram-positive bacteria using tylosin as a control, a 
16-membered macrolide antibiotic usually used in the 
treatment for various infections of animals [19, 20]. 
Compound 1 showed identical antimicrobial activity as 
compound 2, but their activity was less than that of tylo-
sin against most of the tested strains (Table 2). All three 
compounds could not inhibit the growth of Staphylococ-
cus epidermidis at 100  μg/ml. However, it is intriguing 
that compound 1 and compound 2 significantly inhib-
ited the growth of S. pneumoniae and their MICs were 
more than ten folds lower than that of tylosin (Table 2). 
The results indicated that compound 1 and compound 
2 are probably promising new derivatives of tylosin for 
further structural optimization.
Discussion
It is imperative to find novel families of antibiotics for 
tackling evolving pathogens. Streptomyces serves as the 
main source of antibiotics, despite most secondary meta-
bolic pathways are silent or poorly expressed. Based on 
metabolic pathways and regulatory mechanisms of anti-
biotic biosynthesis, specific manipulation on key gene is 
feasible to redirect metabolic flux to the target metabo-
lites, such as heterologous expression of the whole clus-
ter, repressor deletion or activator enhancement, and so 
on. Those approaches enabled the discovery of numer-
ous novel antibiotics [6]. However, a large proportion of 
secondary metabolic pathways in Streptomyces have not 
been unveiled. Therefore, it has become necessary to 
devise methods and strategies to identify these valuable 
secondary metabolites.
WblA of S. ansochromogenes 7100 shares 96 % sequence 
identity with that of S. coelicolor, and is a new member 
of pleiotropic regulators. Disruption of wblA influenced 
the morphological differentiation and the production 
of antibiotics in many Streptomyces spp. [13, 14]. As 
expected, the disruption of wblA in S. ansochromogenes 
Fig. 4 Identification of compound 1 and 2 produced by ΔwblA. HPLC chromatograms (a) and the UV absorption spectra of compound 1 and 2 (b). 
(I): purified compound 1, (II): purified compound 2, (III): fermentation broth from ΔwblA
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7100 influenced spore formation and also abolished nik-
komycin production, but led to the biosynthesis of two 
novel tylosin analogues. WblA can serve as a down-reg-
ulator or activator depending on the species of the strain 
probably via the iron-sulfur cluster in the molecule for 
sensing environmental signals, such as O2 or nitric oxide 
[21, 22]. In S. ansochromogenes 7100, WblA exerted dual 
function in antibiotic biosynthesis, demonstrating that 
the regulators of this family play important roles. Other 
pleiotropic regulators widely exist in many species of 
Streptomyces, such as AdpA and BldA controlling more 
than one pathway [23, 24]. It is applicable to obtain new 
compounds from the cell secondary metabolite reservoir 
by disrupting a single pleiotropic gene without know-
ing details about the mechanism or the pathway of the 
metabolite biosynthesis. So far, exact regulatory mecha-
nism of WblA and its orthologues regulating antibiotics 
biosynthesis are still unknown.
Fig. 5 Structural determinations of compound 1 and compound 2. a 1H NMR of compound 1. b 13C NMR of compound 1. c The structure of com-
pound 1. d 1H NMR of compound 2. e 13C NMR of compound 2. f The structure of compound 2. g The structure of tylosin. Active groups contribut-
ing to tylosin activity are indicated by dashed line. The structural differences among tylosin, compound 1 and compound 2 are shown in red
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Structure determination revealed that compound 1 and 
compound 2 are tylosin analogues. Tylosin can inhibit 
bacterial growth by binding to the large ribosomal subu-
nit to block the peptide tunnel [25]. Despite the structure 
difference at C6, compound 1 and compound 2 showed 
similar antibacterial activity, indicating that ethyl group 
at C6 position is replaceable with hydroxyl group with-
out compromising the antibacterial activity (Fig.  5g). 
Compared to tylosin, the activity of compound 1 and 
compound 2 against most indicator strains was much 
lower. The reduction in activity of these compounds may 
be resulted from the absence of some active groups con-
tributing to the tylosin activity, such as the aldehyde at 
C6 position, dimethyl amino as well as the saccharide 
moieties at C5 (Fig. 5c, f ). No inhibitory activity against 
Staphylococcus epidermidis was observed with com-
pound 1, compound 2 and tylosin at 100  μg/ml. How-
ever, very interestingly, compound 1 and compound 2 
exhibited much higher activity against Streptococcus 
pneumoniae than tylosin (Table 2). S. pneumoniae strain 
with certain resistance to tylosin is probably due to the 
evolvement of pathogenic strains. Ribosome mutation is 
one way to obtain resistance to ribosome-targeted drugs. 
It was reported that replacing G2099 of ribosome with 
dimethyl adenine in Haloarcula marismortui triggered 
sterically clashing with dimethyl amino group linked to 
the saccharide moieties of tylosin and then the resist-
ance was induced [26]. For compound 1 and compound 
2, the reduced molecular size lacking dimethyl amino 
and saccharide branch at C5 could be beneficial for the 
compound to be accommodated into the ribosome tun-
nel of pathogenic strains. These results suggested that 
compound 1 and compound 2 could serve as starting 
molecules for further structural optimization to produce 
diverse bioactive agents, which are constantly required to 
combat the evolving pathogens and new diseases.
Conclusions
Two novel tylosin analogues were generated by ΔwblA. 
Interestingly, the activity of compound 1 and compound 
2 against S. pneumoniae was much higher than that of 
tylosin. They might serve as new derivatives of tylosin for 
property improvement by engineering combinatorial bio-
synthesis of metabolic pathways.
Table 1 Summary of 1H and 13C NMR data for compound 1 
and compound 2 in CDCl3
In this table, s singlet, d doublet, m multiplet, br broad
* Overlapping with other signals
Position Compound 1 Compound 2
δ (1H, mult., J) 13C (δ) δ (1H, mult., J) 13C (δ)
1 174.7 174.7
2 1.92 (1H, d, 16)
2.5 (1H, dd, 17, 10.7)
39.2 1.92 (1H, d, 16)
2.5 (1H, dd, 17, 10.7)
39.2
3 3.72 (1H, d, 10.0) 67.1 3.72 (1H, d, 10.0) 66.8
4 1.48 (1H, *) 39.9 1.48 (1H, *) 39.9
5 4.1 (1H, d, 13.0) 71.6 3.77 (1H, d, 9.0) 72.6
6 4.3 (1H, *) 67.9 1.3 (1H, *) 38
7 2.0 (1H, m)
1.56 (1H, *)
29.2 1.42 (1H, m)
1.57 (1H, *)
32.7
8 2.8 (1H, br) 45.1 2.7 (1H, br) 45.1
9 204 204
10 6.34 (1H, d, 15.0) 118.3 6.33 (1H, d, 15.0) 118.6
11 7.32 (1H, d, 15.0) 148.1 7.32 (1H, d, 15.0) 147.8
12 135.1 135.5
13 5.92 (1H, d, 10.0) 141.9 5.92 (1H, d, 10.0) 141.7
14 2.98 (1H, m) 45.1 2.98 (1H, m) 45.1
15 4.98 (1H, ddd, 10.0, 
10.0, 2.0)
75.3 4.98 (1H, ddd, 10.0, 
10.0, 2.0)
75.2
16 1.88 (1H, m)
1.63 (1H, *)
25.4 1.88 (1H, m)
1.63 (1H,*)
25.5
17 0.94 (3H, *) 9.5 0.94 (3H, *) 9.5
18 1.0 (3H, d, 6.0) 9.5 1.0 (3H, d, 6.0) 9.6
19 1.22 (3H, d, 7.0) 17.6 1.62 (1H, *)
1.3 (1H, *)
22.7
20 1.81 (3H, s) 13.2 0.92 (3H, *) 9.4
21 4.01 (1H, dd, 9.0, 4.0)
3.55 (1H, *)
69.1 1.23 (3H, d,7.0) 17.6
22 1.81 (3H, s) 13.2
23 4.01 (1H, dd, 9.0, 4.0)
3.55 (1H, *)
69
1` 4.58 (1H, d, 7.5) 101.1 4.58 (1H, d, 7.5) 101.1
2` 3.04 (1H, dd, 7.5, 2.5) 81.5 3.04 (1H, dd, 7.5, 2.5) 81.5
3` 3.77 (1H, d, 9.0) 79.8 3.77 (1H, d, 9.0) 79.8
4` 3.2 (1H, m) 72.6 3.2 (1H, m) 72.6
5` 3.53 (1H, *) 70.5 3.53 (1H, *) 70.5
6` 1.29 (3H, *) 17.7 1.29 (3H, *) 17.7
7` 3.5 (3H, s) 59.7 3.5 (3H, s) 59.7
8` 3.63 (3H, s) 61.9 3.63 (3H, s) 61.9
Table 2 Antimicrobial activities of  compound 1, 2 and   
tylosin
Bacteria MIC (μg/ml)
Compound 1 Compound 2 Tylosin
Streptococcus pneumoniae 7.06 7.31 >100
Streptococcus pyogenes 3.53 3.65 0.2
Staphylococcus epidermidis >100 >100 >100
Staphylococcus aureus 56.5 58.5 0.4
Bacillus subtilis 14.1 14.6 0.4
Bacillus cereus 28.2 29.2 0.4
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Methods
Strains, plasmids, primers and growth conditions
Strains and plasmids used in this study are listed in 
Table  3, and the primers used in this study are listed 
in Table  4. Streptomyces ansochromogenes 7100, a nat-
ural nikkomycin producer, and its derivatives were 
grown at 28 °C. SP medium (3 % mannitol, 1 % soluble 
starch, 0.75 % yeast extract and 0.5 % soy peptone, pH 
6.0) was prepared for the production of antibiotics as 
described previously [27]. Agar minimal medium (MM) 
supplemented with mannitol as sole carbon source for 
sporulation was prepared [28]. Escherichia coli JM109, 
routinely used as a host for propagation of plasmids, 
was grown in Luria–Bertani (LB) medium at 37  °C. 
ET12567/pUZ8002 was used for conjugal transfer of 
DNA from E. coli to Streptomyces [28]. Tylosin tartrate 
was purchased from Sigma Aldrich, and used as a con-
trol in bioassays. All fungal strains used as indicators in 
this study except C. albicans were incubated for 5 days 
in PDA at 28  °C. C. albicans was grown in PDA for 
overnight at 37 °C.
Construction of recombinant strains
To construct the wblA disruption mutant (ΔwblA) of S. 
ansochromogenes 7100, the DNA fragment correspond-
ing to the upstream region of wblA was amplified by PCR 
using primers LwblA-F and LwblA-R, and then it was 
digested with HindIII and XbaI. The pwblA1 was con-
structed by inserting above PCR product into the same 
sites of pKC1139. The DNA fragment corresponding to 
the downstream region of wblA was amplified by PCR 
using primers RwblA-F and RwblA-R, followed by diges-
tion with BamHI and EcoRV and inserted into the same 
sites of pwblA1 to generate pwblA2. Kanamycin resist-
ance gene was amplified by PCR using primers Kan-F 
and Kan-R followed by digestion with BamHI and XbaI, 
and inserted into the same sites of pwblA2 to generate 
pwblA3. Subsequently, pwblA3 was introduced into S. 
ansochromogenes 7100 via ET12567/pUZ8002 by con-
jugal transfer. The transformants resistant to kanamycin 
(Kanr) but sensitive to apramycin (Aprs) were selected 
and further confirmed by PCR using primers wblAJ-F 
and wblAJ-R. For complementation analysis, the frag-
ment containing the intact wblA with its putative pro-
moter region was amplified using primers CwblA-F and 
CwblA-R, and inserted into the EcoRV site of pSET152 to 
generate pSET152::wblA. Subsequently, pSET152::wblA 
was introduced into ΔwblA by conjugal transfer, and the 
resulting complemented strain was further confirmed 
by PCR. The null mutant was constructed by integrating 
pSET152 vector into the chromosome of ΔwblA as a con-
trol. All PCR amplicons were confirmed by sequencing.
Table 3 Strains and plasmids used in this study
CGMCC China General Microbiological Culture Collection Center
Name Description Sources
Strains
 S. ansochromogenes 7100 Wild-type strain [27]
 ΔwblA The ORF of whlA consists of 339 bp, and 230 bp of them was  
replaced by kanamycin resistance gene (neo)
This study
 ΔwblA/pSET152::wblA The complemented strain of ΔwblA This study
 Escherichia coli JM109 recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, Δ(lac-proAB)/F’  
[traD36, proAB + lacIq, lacZΔM15]
Invitrogen
 Escherichia coli ET12567/pUZ8002 dam dcm hsdS cat tet/pUZ8002 [31]
 Staphylococcus aureus CGMCC1.89 Indicator strain for bioassays CGMCC
 Bacillus subtilis CGMCC1.1630 Indicator strain for bioassays CGMCC
 Bacillus cereus CGMCC1.1626 Indicator strain for bioassays CGMCC
 Candida albicans CGMCC2.4159 Indicator strain for bioassays CGMCC
 Alternaria longipes CGMCC3.2946 Indicator strain for bioassays CGMCC
Plasmids
 pwblA-DM Plasmid used for the construction of ΔwblA This study
 pSET152:: wblA pSET152 containing the intact wblA with its putative promoter This study
 pSET152 Integrative vector [32]
 pKC1139 E. coli-Streptomyces shuttle vector [28]
 pBluescript KS+ Routine cloning and subcloning vector Stratagene
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RNA isolation and qRT‑PCR
Total RNA was isolated from Streptomyces, and quan-
titative Real Time PCR (qRT-PCR) was performed as 
described previously [29].
Microscopy
For scanning electron microscopy, colonies were fixed in 
2.5 % (v/v) glutaraldehyde for 4 h, stained with osmic acid 
for 2–4 h and dehydrated with ethanol at different concen-
trations. Each sample was coated with platinum-gold and 
then examined with a Hitachi D-570 scanning microscope.
Detection of nikkomycin and tylosin analogues
Nikkomycin was detected by disk agar diffusion and 
HPLC as previously described [30]. The detection of 
tylosin analogues was performed by HPLC on an Agilent 
1260 system equipped with a ZORBAX SB-C18 reverse 
phase column (4.6 ×  250 mm, 5 μm, Agilent). Samples 
were eluted at 1 ml/min with a linear gradient from 50 
to 80 % of methanol in water over 25 min at wavelength 
of 280 nm. Each experiment was performed in triplicate.
Isolation and structural determination of compound 1 
and 2
For antibiotics production, spore suspensions were inoc-
ulated into liquid SP medium and cultured at 28  °C for 
24  h as seed culture in shake flask (220 revolutions per 
minute, rpm), and then 30 ml of seed culture was trans-
ferred to 3 L of SP in a 5 L fermentor (BIOTECH-5JG, 
BX-BIO). BIOTECH-FCS software was used to control 
the equipment and collect data. Air was sparged into 
the fermentor to supply oxygen at four times  atmos-
pheric pressure, and the rotor speed was 400 rpm. After 
fermentation for 5  days at 28  °C the culture broth of 
ΔwblA was filtered by Pyrex Buchner funnel with a frit-
ted disc (pore size 40–60  mm). Then the supernatant 
was extracted by separatory funnel with equal volume of 
chloroform for three times at room temperature. Chloro-
form extract was evaporated to dry. The resulting sam-
ple was re-dissolved in methanol and then separated on 
Sephadex LH-20 as mentioned above. Active fractions 
were collected and purified by semi-preparative HPLC 
equipped with ZORBAX SB-C18 reverse phase column 
(9.4 × 250 mm, 5 μm, Agilent) by linear gradient elution 
as mentioned above.
MS analysis was performed on LTQ Orbitrap hybrid 
mass spectrometer (Thermo-Fisher) equipped with a 
Dionex Ultimate 3000 nano-flow system and a nano-
electrospray ion source. NMR spectra were recorded 
on a 500 MHZ Bruker spectrometer using CDCl3 as the 
solvent.
Determination of minimum inhibitory concentration (MIC)
Compound 1, 2 and tylosin standard were dissolved in 
DMSO and serially diluted with LB prior to mixing with 
indicator strains. Indicator strains were pre-incubated 
in LB on a rotary shaker at 37  °C for overnight. Assays 
for determining MIC were performed on 96-well plates 
consisting of the diluted compounds, indicator strains 
(0.5 %) and 0.5 % DMSO. Strains growing in LB medium 
containing 0.5  % DMSO without test compounds were 
used as positive controls, and LB medium containing 
0.5 % DMSO was used as negative control. The growth of 
indicator strains was measured after 12  h of incubation 
for S. epidermidis, S. aureus, B. subtilis and B. cereus, and 
24 h for S. pneumoniae and S. pyogenes on a microplate 
reader (Synergy H4, Biotech) at wavelength of 600  nm. 
Each experiment was performed in triplicate.
Additional file
Additional file 1. Figure S1. NMR Spectra of compound 1. (A) Summary 
of key correlations between protons and carbons in compound 1 based 
on NMR spectroscopic data. (B) 1H-1H COSY spectrum of compound 1. 
(C) 1H-13C HSQC spectrum of compound 1. (D) 1H-13C HMBC spectrum 
of compound 1. Figure S2. NMR Spectra of compound 2. (A) Summary 
of key correlations between protons and carbons in compound 2 based 
on NMR spectroscopic data. (B) 1H-1H COSY spectrum of compound 2. 
(C) 1H-13C HSQC spectrum of compound 2. (D) 1H-13C HMBC spectrum 
of compound 2. Table S1. Antimicrobial activities of fermentation broth 
from S. ansochromogenes 7100 and ΔwblA by agar diffusion assays.
Table 4 Primers used in this study
Primers Sequence (5′‑3′)
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